08.14.26 -- Accelerate Development, Reduce Risk, And Advance Programs With Confidence

Strategic planning in early-phase biologics accelerates clinical progress, reduces risk, and lays the groundwork for scalable, compliant manufacturing and successful commercialization.

As an integrated CRO/CDMO combines formulation and pharmacy expertise to optimize drug products, support clinical trials, and help resolve challenges that could impact development timelines.

To avoid costly delays later in the product lifecycle, it is essential to plan for key variables early and select container closure systems with confidence from the outset.

Adopt integrated, end-to-end clinical supply strategies that enable self-administered therapies, reduce patient burden, and accelerate clinical trial timelines while improving access and outcomes.

Drug delivery strategy drives effectiveness and outcomes. Advances in formulation and dosing enable precise, scalable solutions to overcome development challenges and boost performance.

This session is designed to help you assess which development strategies, timelines, and geographic options may be best suited for your asset, providing practical insights to support informed decision-making and accelerate your path to clinic.

A lifecycle‑based analytical framework supporting release testing, stability studies, and product characterization to boost regulatory readiness, cut variability, and speed development.

End-to-end development, manufacturing, packaging, and logistics streamline complex drug programs and support efficient progress from formulation to global clinical supply.

Accelerate your pharmaceutical development with end-to-end support, global softgel expertise, and the strategic advantages of a New Zealand-based manufacturing partner.